Literature DB >> 15911863

Trastuzumab plus chemotherapy: convincing survival benefit or not?

Charles L Vogel, Elizabeth Tan-Chiu.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15911863     DOI： 10.1200/JCO.2005.12.903

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  4 in total

1.  A case of HER-2-positive advanced inflammatory breast cancer with invasive micropapillary component showing a clinically complete response to concurrent trastuzumab and paclitaxel treatment.

Authors:  Hideo Shigematsu; Yoshiaki Nakamura; Kimihiro Tanaka; Satoko Shiotani; Chinami Koga; Hidetoshi Kawaguchi; Sumiko Nishimura; Kenichi Taguchi; Kenichi Nishiyama; Shinji Ohno
Journal:  Int J Clin Oncol       Date:  2010-05-15       Impact factor: 3.402

2.  Meta-analysis of concomitant compared to sequential adjuvant trastuzumab in breast cancer: the sooner the better.

Authors:  Fausto Petrelli; Sandro Barni
Journal:  Med Oncol       Date:  2011-03-13       Impact factor: 3.064

3.  Translating cancer trial endpoints into the language of managed care.

Authors:  Allan Jay Kogan; Melinda Haren
Journal:  Biotechnol Healthc       Date:  2008-05

4.  Efficacy control of therapy using circulating epithelial tumor cells (CETC) as "liquid biopsy": trastuzumab in HER2/neu-positive breast carcinoma.

Authors:  Katharina Pachmann; O Camara; T Kroll; M Gajda; A K Gellner; J Wotschadlo; I B Runnebaum
Journal:  J Cancer Res Clin Oncol       Date:  2011-07-08       Impact factor: 4.553
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.